Fruitful partnerships

VelosBio marks the first start-up to emerge from Arix’s partnerships

Arix Bioscience plc (LSE:ARIX) leveraged its partnership with Takeda Ventures to co-lead a $58 million series A round for antibody-drug company VelosBio Inc., a sign that the VC’s strategic partnerships are finally bearing fruit.

Also participating

Read the full 351 word article

User Sign In